KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Arbutus Biopharma (ABUS) Operating Expenses: 2009-2024

Historic Operating Expenses for Arbutus Biopharma (ABUS) over the last 16 years, with Dec 2024 value amounting to $82.5 million.

  • Arbutus Biopharma's Operating Expenses fell 59.66% to $9.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $61.4 million, marking a year-over-year decrease of 31.67%. This contributed to the annual value of $82.5 million for FY2024, which is 14.29% down from last year.
  • Per Arbutus Biopharma's latest filing, its Operating Expenses stood at $82.5 million for FY2024, which was down 14.29% from $96.2 million recorded in FY2023.
  • Arbutus Biopharma's Operating Expenses' 5-year high stood at $104.5 million during FY2022, with a 5-year trough of $64.7 million in FY2020.
  • Its 3-year average for Operating Expenses is $94.4 million, with a median of $96.2 million in 2023.
  • Its Operating Expenses has fluctuated over the past 5 years, first plummeted by 56.83% in 2020, then skyrocketed by 30.58% in 2021.
  • Over the past 5 years, Arbutus Biopharma's Operating Expenses (Yearly) stood at $64.7 million in 2020, then spiked by 30.58% to $84.5 million in 2021, then grew by 23.62% to $104.5 million in 2022, then dropped by 7.88% to $96.2 million in 2023, then dropped by 14.29% to $82.5 million in 2024.